

Establishment and Verification of Prognostic Nomograms for Young Women With Breast Cancer Bone Metastasis

Zhan Wang^{1,2,3*†}, Haiyu Shao^{1,2,3,4†}, Qiang Xu^{5†}, Yongguang Wang¹, Yaojing Ma^{1,2,3}, Diarra Mohamed Diaty^{1,2,3}, Jiahao Zhang^{1,2,3} and Zhaoming Ye^{1,2,3*}

¹ Department of Orthopedic Surgery, The Second Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, China, ² Orthopedics Research Institute of Zhejiang University, Hangzhou, China, ³ Key Laboratory of Motor System Disease Research and Precision Therapy of Zhejiang Province, Hangzhou, China, ⁴ Department of Orthopedics, Zhejiang Provincial People's Hospital (Affiliated People's Hospital, Hangzhou Medical College), Hangzhou, China, ⁵ Department of Orthopaedics, Xuzhou Central Hospital, Xuzhou, China

OPEN ACCESS

Edited by:

Enrico Capobianco, University of Miami, United States

Reviewed by:

Xiaowei Qi, Southwest Hospital, Army Medical University, China Tino Unlap, University of Alabama at Birmingham, United States

*Correspondence:

Zhan Wang wangzhanhz@zju.edu.cn Zhaoming Ye yezhaoming@zju.edu.cn †These authors have contributed equally to this work

Specialty section:

This article was submitted to Translational Medicine, a section of the journal Frontiers in Medicine

Received: 20 December 2021 Accepted: 17 February 2022 Published: 12 April 2022

Citation:

Wang Z, Shao H, Xu Q, Wang Y, Ma Y, Diaty DM, Zhang J and Ye Z (2022) Establishment and Verification of Prognostic Nomograms for Young Women With Breast Cancer Bone Metastasis. Front. Med. 9:840024. doi: 10.3389/fmed.2022.840024 **Purpose:** The prognosis of patients with metastatic breast cancer usually varies greatly among individuals. At present, the application of nomogram is very popular in metastatic tumors. The present study was conducted to identify independent survival predictors and construct nomograms among young women with breast cancer bone metastasis (BCBM).

Patients and Methods: We searched the Surveillance, Epidemiology, and End Results (SEER) database to identify young women diagnosed with BCBM between 2010 and 2016. We first analyzed the potential risk factors of overall survival (OS) and cancer-specific survival (CSS) by applying univariate Cox regression analysis. Then we conducted multivariate Cox analysis to identify independent survival predictors. Based on significant independent predictors, we developed and validated novel prognostic nomograms by using the R version 4.1.0 software.

Results: We finally identified 715 eligible young women with BCBM for survival analysis, of which 358 patients were in the training set, and 357 patients in the validation set. Approximately four-fifths of patients are between 31 and 40 years old. The 5-year OS and CSS rates of this research population were 41.9 and 43.3%, respectively. Multivariate analysis revealed seven independent predictors of both OS and CSS, including race, tumor subtype, tumor size, surgical treatment, brain metastasis, liver metastasis, and lung metastasis. Based on these predictors, we developed and validated OS and CSS nomograms. The C-index of the OS nomogram reached 0.728 and 0.73 in the training and validation sets, respectively. The C-index of the CSS nomogram reached 0.743 and 0.695 in the training and validation sets, respectively. Meanwhile, high quality calibration plots were revealed in both OS and CSS nomograms.

Conclusion: The current novel nomograms can provide an individualized survival evaluation of young women with BCBM and instruct clinicians to treat them appropriately.

Keywords: young women, breast cancer, bone metastasis, nomogram, survival, predictor

1

INTRODUCTION

Although female breast cancer (BC) under the age of 40 accounts for about 7-10% of all BCs (1), it is the most common malignant tumor among young patients (2). Moreover, young BC is the leading cause of cancer death in this age group (3). Previous studies have shown that young BC patients present with more aggressive clinical characteristics and poor outcome compared with elderly (2, 4, 5). However, young metastatic BC patients might have better prognosis than elderly patients (6). BC most often metastasizes to the bone, which not only negatively affects the quality of life of patients, but also affects the longevity of patients (7). Although the diagnosis and treatment of BC has made great progress, bone metastasis is still a significant challenge for clinicians. Currently, there are limited studies on the clinical features and prognosis of young women with breast cancer bone metastasis (BCBM).

Currently, driven by the clinical needs, more and more researchers focus on establishing clinical models for predicting the outcome and guiding the clinical management (8, 9). Nomogram as a popular quantitative predictive model, has been successfully applied to calculate and predict the survival of cancer patients (10, 11). More importantly, nomograms can ensure the accuracy of prognostic prediction and visually display patients' prognosis prediction results. To the best of our knowledge, there are limited studies on the clinical characteristics and survival prediction of women patients with BCBM under age 40. This is the first presentation of developing and validating novel nomograms of young women patients with BCBM by using the Surveillance, Epidemiology, and End Results (SEER) database.

MATERIALS AND METHODS

Patients Selection

Clinical data from the SEER database on young BCBM were obtained by using the case-listing session on the SEER*Stat version 8.3.9 software. We selected the primary tumor sites of BC by using the Site recode ICD-O-3/WHO 2008 "Breast." Meanwhile, we set the Age at diagnosis to be <40 years and SEER Combined Mets at DX-bone (2010+) to be YES. As a result, we obtained clinical information on all young BC patients with bone metastasis. Male patients and patients with other unknown variables were excluded. This study collected patients' information from a public database and did not contain any patientidentified information. Thus, this study was exempted from medical ethics review.

We obtained data from the SEER database, including race, age at diagnosis, gender, laterality, tumor grade, histological type, tumor subtype, tumor size, surgery, radiotherapy, chemotherapy, visceral metastasis, vital status, survival time, and cause of death. The "young OS, overall survival, CSS, cancer-specific survival.

TABLE 1 | Demographics of 715 young breast cancer bone metastasis.

Variable	Value
Race	
White	496(69.4%)
Black	142(19.9%)
Others	77(10.8%)
Age(years)	
20–30	125(17.5%)
31–40	590(82.5%)
Laterality	
Left	358(50.1%)
Right	357(49.9%)
Tumor grade	
Low grade (I/II)	327(45.7%)
High grade (III/IV)	388(54.3%)
Histological type	
Infiltrating duct carcinoma, NOS	603(84.3%)
Others	112(15.7%)
Tumor subtype	
	379(53.0%)
	202(28.3%)
HEB21	67(9.4%)
	67(9.4%)
Tumor size (om)	07 (9.470)
	000/00 00/
<0	209(29.2%)
3-0	294(41.1%)
>0	212(29.7%)
Surgery	000/44.00//
Yes	320(44.8%)
	395(55.2%)
Radiotherapy	0.10/17.00/
Yes	340(47.6%)
No	375(52.4%)
Chemotherapy	
Yes	598(83.6%)
No	117(16.4%)
Brain metastasis	
No	678(94.8%)
Yes	37(5.2%)
Liver metastasis	
No	501(70.1%)
Yes	214(29.9%)
Lung metastasis	
No	584(81.7%)
Yes	131(18.3%)
Lymph node metastasis	
No	127(17.8%)
Yes	588(82.2%)
Dead	
Yes	268(37.5%)
No	447(62.5%)
3-year OS rate	61.50%
3-year CSS rate	62.60%
5-year OS rate	41.90%
5-vear CSS rate	43.30%





FIGURE 2 | The graph shows the nomogram predicting 3- and 5-year cancer-specific survival of young women with breast cancer bone metastasis. The nomogram summed the points identified on the scale for each predictor. The total points projected on the bottom scales indicate the probabilities of 3- and 5-year overall survival.

breast cancer" was defined as women aged under 40 years. Surgery or radiotherapy in the present study refers to treatment for breast cancer. According to previous studies (12, 13), overall survival (OS) and cancer-specific survival (CSS) were defined as the time from diagnosis to the time of death attributed to any cause and breast cancer, respectively. Both OS and CSS were used as endpoints of the present study.

HR (65% CI) P HR (65% CI) P Rec 1 1 1 Black 2.026 (1.301-2.852) < 0.001 1.576 (1.443-2.907) 0.001 Chrons 0.850 (0.493-1.658) 0.989 1.141 (0.61-1.898) 0.021 Age (berns) 1 1 1 3	Variable	os		CSS		
Race 1 1 While 1 1 Block 2.026 (1.391-2.9262) <0.001 1.976 (1.343-2.307) 0.001 Others 0.850 (0.485-1.559) 0.599 1.141 (0.661-1.969) 0.638 Age (yars) 20-30 1 1 1 31-40 1.025 (0.67-1.575) 0.911 1.033 (0.655-1.632) 0.889 Laterally 1 <th></th> <th>HR (95% CI)</th> <th>Р</th> <th>HR (95% CI)</th> <th>Р</th>		HR (95% CI)	Р	HR (95% CI)	Р	
While11Black2.02 (1.391-2.35.2)0.0391.141 (0.661-1.369)0.039Others0.590 (0.463-1.559)0.5991.141 (0.661-1.369)0.639Age (sers)11131-401.025 (0.667-1.575)0.9111.033 (0.655-1.032)0.889Laterality1111Bight1.011 (0.720-1.419)0.6490.899 (0.648-1.247)0.524Ling grade (M)1111High grade (M)/M1.61 (1.57-2.27.5)0.0091.394 (1.00-1.944)0.055Histogical Vige1111Other actionizationi	Race					
Black2.026 (1.361-2626)<.0.011.76 (1.343-2.07)0.001Othes0.5690.176 (1.343-2.07)0.001Othes0.5690.176 (1.343-2.07)0.088Jardot1.27 (0.067-1.57)0.9111.033 (0.565-1.32)0.888Laterally111Endit1110.524Low grade (II/M)1.6 (1.156-2.27)0.0090.399 (0.648-1.247)0.524Low grade (II/M)1.6 (1.156-2.27)0.0090.394 (1.000-1.344)0.052Throur grade1110.001Unor grade (II/M)1.6 (1.156-2.27)0.0090.349 (0.088-1.020)0.049Unor grade (II/M)1.6 (1.156-2.27)0.0090.349 (0.088-1.020)0.010Charles (III/C)1110.001Others0.095 (0.060-1.37)0.0050.498 (0.368-1.030)0.017Unor grade1110.0050.001Charles (III/C)0.0110.120 (0.688-1.042)0.065Throu grade (III/C)110.0110.011Unor grade (III/C)110.0110.011Unor grade (III/C)110.0110.011Unor grade (III/C)10.0110.0110.0110.011Unor grade (III/C)10.01110.0110.0110.011Unor grade (III/C)110.0110.0110.0110.0110.011Unor grade (IIII/C)110.0	White	1		1		
Others0.680 (0.483-1.569)0.5691.141 (0.681-1.509)0.683Age years20-3011131-401.05 (0.687-1.575)0.9110.085-1.632)0.888Latrallay111Right1.01 (0.72-1.419)0.5490.589 (0.48-1.247)0.524Latrallay1111High grade (WM)1111High grade (WM)1.61 (1.25-2.275)0.0091.384 (1.00-1.844)0.05Histogical type1111Umb grade (WM)1.4247 0.818-1.903)0.3050.6849 (0.528-1.963)0.498Tigh grade (WA)11111Lunnka J111111Lunnka J111 </td <td>Black</td> <td>2.026 (1.391-2.952)</td> <td>< 0.001</td> <td>1.976 (1.343–2.907)</td> <td>0.001</td>	Black	2.026 (1.391-2.952)	< 0.001	1.976 (1.343–2.907)	0.001	
Apply 20-3011120-3010.25 0.067-1.576)0.9111.033 0.0656-1.632)0.0880LateralEnt11.033 0.0656-1.632)0.0890Ent110.0990Enty and 20000.09900.0890 0.064-0.247)0.524Enty and 20001.011 0.720-1.419)0.9490.899 0.064-0.247)0.524Enty and 20001110.000Enty and 20001.534 (1.00-0.1.344)0.051.000 0.064-0.1247)0.052Enty and 200010.0101.334 (1.00-0.1.344)0.051.000 0.0650.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0000.0000.0000.0000.0000.0000.0010.	Others	0.850 (0.463-1.559)	0.599	1.141 (0.661–1.969)	0.636	
20-30 1 1 1 31-40 1.058 (0.657-1.575) 0.911 1.033 (0.557-1.632) 0.888 Lebraility 1 1 1 Endit 1 1 0.898 0.898 (0.68-12.47) 0.524 Tumo grade 1 1 1 0.898 (0.68-12.47) 0.524 Tumo grade (0/1) 1.01 (0.72-0.149) 0.899 (0.68-12.47) 0.524 High grade (0/1) 1.01 (0.72-0.149) 0.899 (0.68-1.27) 0.524 High grade (0/1) 1.01 (0.72-0.149) 0.899 (0.59-1.363) 0.498 High grade (0/1) 0.101 0.690 (0.42-1.697) 0.692 (0.110,457-1.105) 0.498 Luminal B 0.670 (0.42-1.067) 0.692 (0.110,457-1.105) 0.498 0.490 (0.69-1.394) 0.697 Luminal B 0.670 (0.42-1.067) 0.692 (0.110,457-1.493) 0.697 1.01 0.697 Luminal B 0.670 (0.42-1.067) 0.698 1.130 (0.642 (0.398-1.324) 0.697 Luminal B 0.670 (0.42-1.067) 0.698 1.137 (0.642 (0.398) 0.001	Age (years)					
31-401.028 (0.667-1.578)0.9111.033 (0.655-1.632)0.888LateralityLeft11Right1.011 (0.720-1.419)0.9490.899 (0.646-1.247)0.524Tomor grade11Um grade (ll(N)111High grade (ll(N)1.61 (1.25-2.275)0.090.384 (1.000-1.944)0.056Histological Uype111Inflatang duct caranoma, NOS111Chrone grade (ll(N)1.111Chrone grade (ll(N)1.111Luminal A111Luminal B0.059 (0.569-1.739)0.0851.130 (0.656-1.942)0.065Tople scattering11333Luminal B1.527 (0.538-9.272)0.0101.752 (1.142-6.369)0.011Star Core11333Luminal B1.527 (1.127-6.319)0.0051.367 (1.514-3.017)0.001Star Core111333Luminal B111333	20–30	1		1		
Laterality in the second seco	31–40	1.025 (0.667-1.575)	0.911	1.033 (0.655-1.632)	0.888	
Left 1 1 Right 1.011 (0.270-1.413) 0.349 0.389 (0.649-1.247) 0.524 Tumor grade 1 1 1 1 High grade (WM) 1	Laterality					
<table-container>Fight1.011 (0.720-1.419)0.9490.839 (0.648-1.247)0.524Tumor gradeLow grade (I/IV)1.6 (1.125-2.275)0.0091.394 (1.000-1.944)0.05Histological typeUnificating duc carcinoma, NOS11Others1.247 (0.818-1.903)0.3050.849 (0.529-1.363)0.449Unificating duc carcinoma, NOS11Unificating duc carcinoma, NOS111Unificating duc carcinoma, NOS1.67 (0.421-1.067)0.0300.849 (0.529-1.363)0.408Tuminal B0.670 (0.421-1.067)0.0920.711 (0.457-1.105)0.130.655Tiple-negative5.724 (3.533-9.272)<0.0016.425 (3.983-10.365)<0.001Tumina F11111Section1.752 (1.142-2.686)0.011.752 (1.142-2.686)0.010.13Section111111Section1.052 (1.127-2.921)<0.0101.263 (0.930-1.757)0.163Section11111111Ne 11</table-container>	Left	1		1		
Tumor grade Normal State Normal State Low grade (W) 1 1 1 High grade (W)/V 1.6 (1.152-2.275) 0.0009 1.394 (1.00-1.944) 0.056 Histological type 1 1 0 0.0005 Histological type 1 1 0 0.498 Churses 1.247 (0.818903) 0.305 0.5949 (0.529-1.365) 0.498 Tumor subtype 1 1 1 0.001 0.001 0.131 Luminal A 1 0.001 0.425 (3983-10.425) 0.605 0.607 Tumor subtype 2 0.716 (0.421-1.067) 0.092 0.711 (0.457-1.105) 0.131 HER2+ 0.995 (0.563-1.739) 0.085 1.130 (0.658-1.942) 0.607 Tumor size (em) 1 1 1 0.001 1.752 (1.142-2.689) 0.010 1.752 (1.142-2.689) 0.01 1.752 (1.142-2.689) 0.01 1.055 0.011 1.055 0.01 2.017 (0.514-0.01) 0.001 2.017 (0.516 .01) 0.001 0.01 </td <td>Right</td> <td>1.011 (0.720-1.419)</td> <td>0.949</td> <td>0.899 (0.648-1.247)</td> <td>0.524</td>	Right	1.011 (0.720-1.419)	0.949	0.899 (0.648-1.247)	0.524	
Low grade (M)11High grade (M/W)1.6.1.1.2.5-2.2.7.8)0.0091.3.94 (1.0.00-1.9.44)0.05Histological type11Inflittating duct carcinoma, NOS110.050.849 (0.529-1.363)0.489Tumor subtype1111Luminal A11<	Tumor grade					
High grade (HIMY) 1.6 (1.125-2.275) 0.009 1.394 (1.000-1.9.44) 0.05 Histogical type High grade (darchome, NCS) 1 1 Others 1.247 (0.818-1.903) 0.305 0.849 (0.529-1.363) 0.498 Tummal K 1 1 1 Luminal B 0.670 (0.421-1.067) 0.092 0.711 (0.457-1.105) 0.13 HER2+ 0.995 (0.669-1.739) 0.985 1.130 (0.658-1.942) 0.657 Tumor size (cm) 1 1 1 1 Constrained State 1 1 1 1 3-6 1.752 (1.142-2.686) 0.01 1.877 (1.215-2.931) 0.005 Starpe 1 1 1 1 3-6 1.887 (1.215-2.931) 0.005 1.887 (1.215-2.931) 0.005 Starpe 1 1 1 1 1 1 3-6 1.887 (1.215-2.931) 0.001 2.137 (1.51-4.3.017) <0.001 2.137 (1.51-4.3.017) <0.001 Starpe 1 1 1 3.000 3.039 3.039 <td>Low grade (I/II)</td> <td>1</td> <td></td> <td>1</td> <td></td>	Low grade (I/II)	1		1		
Histogical type11Infilter of carcinoma, NOS11Others1.247 (0.816-1.903)0.3050.849 (0.529-1.363)0.498Tumor subtype11Luminal A111Luminal B0.670 (0.421-1.67)0.9920.711 (0.457-1.105)0.13IER2+0.995 (0.569-1.739)0.9951.130 (0.656-1.942)0.657Triple-negative5.724 (3.533-9.272)<0.01	High grade (III/IV)	1.6 (1.125–2.275)	0.009	1.394 (1.000–1.944)	0.05	
Inflitating durancinoma, NOS 1 1 Others 1,247 (0.818-1.903) 0.305 0.849 (0.529-1.363) 0.498 Tumor subtype	Histological type					
Others 1.247 (0.818–1.903) 0.305 0.849 (0.529–1.363) 0.498 Tumo subtype Luminal A 1 1 Luminal A 0.670 (0.421–1.067) 0.092 0.711 (0.457–1.105) 0.18 LER2+ 0.969 (0.569–1.739) 0.995 1.130 (0.658–1.942) 0.6657 Timor size (cm) 1 0.425 (3.983–0.262) <0.001 0.425 (3.983–1.036) <0.001 Timor size (cm) 1 1 0.01 0.01 0.01 0.01 0.01 0.01 0.01 0.01 0.01 0.01 0.01	Infiltrating duct carcinoma, NOS	1		1		
Tumor subtypeInterfaceInterfaceLuminal A11Luminal B0.670 (0.421-1.067)0.0920.711 (0.457-1.105)0.13IER2+0.996 (0.669-1.739)0.9951.130 (0.668-1.942)0.667Triple-negative5.724 (3.533-9.272)<0.001	Others	1.247 (0.818-1.903)	0.305	0.849 (0.529-1.363)	0.498	
Intersection11 <th col<="" td=""><td>Tumor subtype</td><td></td><td>0.000</td><td>01010 (01020 11000)</td><td>0.100</td></th>	<td>Tumor subtype</td> <td></td> <td>0.000</td> <td>01010 (01020 11000)</td> <td>0.100</td>	Tumor subtype		0.000	01010 (01020 11000)	0.100
Internation Internation Internation Luminal B 0.670 (0.421-1.067) 0.092 0.711 (0.477-1.105) 0.13 HEF2+ 0.996 (0.569-1.739) 0.985 1.130 (0.658-1.942) 0.667 Tiple-regative 5.72 (3.533-9.272) <0.001		1		1		
Linked Costs (c.58+1.734) Costs Linked		0.670 (0.421–1.067)	0.092	0 711 (0 457–1 105)	0.13	
Indust Discle (assos (1.05) Close (1.050) Close (1	HEB2+	0.995 (0.569–1.739)	0.985	1 130 (0 658–1 942)	0.657	
Impande Interference Constit	Triple-pegative	5 724 (3 533-9 272)	< 0.000	6 425 (3 983–10 365)	< 0.001	
since (any side (any)11 $3-6$ 1.752 (1.142-2.686)0.011.752 (1.142-2.686)0.01 >6 1.887 (1.215-2.931)0.0051.887 (1.215-2.931)0.005SurgeryVes11No2.510 (1.752-3.598)<0.0012.137 (1.514-3.017)<0.001RadiotherapyVes111No111No11111No11 <td>Tumor size (cm)</td> <td>0.724 (0.000 0.272)</td> <td>< 0.001</td> <td>0.420 (0.000 10.000)</td> <td>< 0.001</td>	Tumor size (cm)	0.724 (0.000 0.272)	< 0.001	0.420 (0.000 10.000)	< 0.001	
xxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxx	3	1		1		
Code 11.02 (11.02 = 2.00) 0.01 11.02 (11.02 = 2.00) 0.01 >6 1.887 (1.215 = 2.931) 0.005 1.887 (1.215 = 2.931) 0.005 Surgery Yes 1 1 1 No 2.510 (1.752 = 3.598) <0.001	3_6	1 752 (1 1/2-2 686)	0.01	1 752 (1 142-2 686)	0.01	
No. 1.001 (1.252.301) 0.000 1.001 (1.252.301) 0.000 Surgery 1 1 1 Yes 1 0 2.137 (1.514-3.017) <0.001 Radiotherapy 1 1 Yes 1 1	5-0 >6	1.887 (1.215-2.031)	0.01	1 887 (1 215-2 031)	0.01	
SubsymptialYes11No $2.510 (1.752-3.598)$ <0.001 $2.137 (1.514-3.017)$ <0.001 RadiotherapyYes111No $1.568 (1.109-2.217)$ 0.011 $1.263 (0.908-1.757)$ 0.165 ChemotherapyYes111No $1.568 (1.109-2.217)$ 0.011 $1.263 (0.908-1.757)$ 0.165 Chemotherapy111No1.058 (1.083-1.847) 0.399 $1.276 (0.848-1.920)$ 0.243 Brain metastasis111No1111Yes $3.235 (1.737-6.023)$ <0.001 $7.323 (4.067-13.185)$ <0.001 Liver metastasis111No1111Yes $2.174 (1.533-3.083)$ <0.001 $2.089 (1.494-2.920)$ <0.001 Liver metastasis111No1111Yes $2.658 (1.571-3.943)$ <0.001 $2.88 (1.94-2.920)$ <0.001 Liph node metastasis111No1111Yes $2.658 (1.571-3.943)$ <0.001 $2.88 (1.94-2.920)$ <0.001 Liph node metastasis111No11111Yes $0.656 (1.571-5.943)$ $0.655 (1.167 (0.758-1.797)$ 0.848	Surgery	1.007 (1.213-2.331)	0.000	1.007 (1.213–2.301)	0.000	
Tes I I I No 2.510 (1.752-3.598) <0.001	Surgery	4		1		
No 2.510 (1.7.2=3.536) C.0.01 2.1.51 (1.514=3.017) C.0.01 Radiotherapy 1 1 1 Yes 1 0.011 1.263 (0.908=1.757) 0.165 Chemotherapy 1 1 2.63 (0.908=1.757) 0.165 Chemotherapy 1 1.203 (0.783=1.847) 0.399 1.276 (0.848=1.920) 0.243 Brain metastasis 1 0 1 0 0.235 (1.737=6.023) <0.001 7.323 (4.067=13.185) <0.001 Ves 3.235 (1.737=6.023) <0.001 7.323 (4.067=13.185) <0.001 Liver metastasis 1 1 <0.001 <0.001 <0.001 Liver metastasis 1 1 <0.001 <0.001 <0.001 <0.001 Lung metastasis 1 1 <0.001 2.80 (1.94=2.920) <0.001 <0.001 <0.001 Lung metastasis 1 <0.001 2.80 (1.94=4.032) <0.001 <0.001 <0.001 <0.001 <0.001 <0.001 <0	No		-0.001		-0.001	
Vision of the second	Redictheren	2.510 (1.752-5.596)	< 0.001	2.137 (1.514-5.017)	< 0.001	
Yes I I I No 1.568 (1.109-2.217) 0.011 1.263 (0.908-1.757) 0.165 Chemotherapy V V I	Radiotherapy	4				
No 1.568 (1.109-2.217) 0.011 1.263 (0.908-1.757) 0.165 Chemotherapy Yes 1 1 1 No 1.203 (0.783-1.847) 0.399 1.276 (0.848-1.920) 0.243 Brain metastasis U 1 1 0.243 No 1 0.399 1.276 (0.848-1.920) 0.243 Brain metastasis U 1 1 0.243 No 1 1 1 0.243 Yes 3.235 (1.737-6.023) <0.001 7.323 (4.067-13.185) <0.001 Liver metastasis U 1 1 <0.001 Chemotherapy <0.001 European	Yes		0.011		0.105	
Ves 1 1 No 1.203 (0.783–1.847) 0.399 1.276 (0.848–1.920) 0.243 Brain metastasis 0.243 Roin metastasis 1 0.399 1.276 (0.848–1.920) 0.243 Brain metastasis 1 1 0.243 No 1 1 1 0.243 0.243 Ves 3.235 (1.737–6.023) <0.001		1.568 (1.109–2.217)	0.011	1.263 (0.908–1.757)	0.165	
Yes 1 1 No 1.203 (0.783–1.847) 0.399 1.276 (0.848–1.920) 0.243 Brain metastasis	Chemotherapy					
No 1.203 (0.783–1.847) 0.399 1.276 (0.848–1.920) 0.243 Brain metastasis	Yes			1	0.040	
Brain metastasis No 1 1 Yes 1 1 Yes 3.235 (1.737–6.023) <0.001 7.323 (4.067–13.185) <0.001 Liver metastasis No 1 1 <	No	1.203 (0.783–1.847)	0.399	1.276 (0.848–1.920)	0.243	
No 1 1 Yes 3.235 (1.737–6.023) <0.001	Brain metastasis					
Yes 3.235 (1.737–6.023) <0.001 7.323 (4.067–13.185) <0.001 Liver metastasis No 1 1 Yes 2.174 (1.533–3.083) <0.001 2.089 (1.494–2.920) <0.001 Lung metastasis <0.001 No 1 1 <0.001 <0.001 <0.001 <0.001 <0.001 <0.001 <0.001 <0.001 <0.001 <0.001 <0.001 <0.001 <0.001 <0.001 <0.001 <0.001 <0.001 <0.001 <0.001 <0.001 <0.001 <0.001 <0.001 <0.001 <0.001 <0.001 <0.001 <0.001 <0.001 <0.001 <0.001 <0.001 <0.001 <0.001 <0.001 <0.001 <0.001 <0.001 <0.001 <0.001 <0.001 <0.001 <0.001 <0.001 <0.001 <0.001 <0.001 <0.001 <0.001 <0.001 <0.001 <0.001 <0.001 <	No	1		1		
Liver metastasis No 1 1 Yes 2.174 (1.533–3.083) <0.001	Yes	3.235 (1.737–6.023)	< 0.001	7.323 (4.067–13.185)	< 0.001	
No 1 1 Yes 2.174 (1.533–3.083) <0.001	Liver metastasis					
Yes 2.174 (1.533–3.083) < 0.001 2.089 (1.494–2.920) < 0.001 Lung metastasis < 0.001 No 1 1 < 0.001 < 0.001 <th<< td=""><td>No</td><td>1</td><td></td><td>1</td><td></td></th<<>	No	1		1		
Lung metastasis No 1 1 Yes 2.658 (1.791–3.943) <0.001	Yes	2.174 (1.533–3.083)	< 0.001	2.089 (1.494–2.920)	< 0.001	
No 1 1 Yes 2.658 (1.791–3.943) <0.001	Lung metastasis					
Yes2.658 (1.791–3.943)<0.0012.8 (1.945–4.032)<0.001Lymph node metastasisNo11Yes0.907 (0.594–1.384)0.651.167 (0.758–1.797)0.484	No	1		1		
Lymph node metastasis 1 1 No 1 1 Yes 0.907 (0.594–1.384) 0.65 1.167 (0.758–1.797) 0.484	Yes	2.658 (1.791–3.943)	< 0.001	2.8 (1.945–4.032)	< 0.001	
No 1 1 Yes 0.907 (0.594–1.384) 0.65 1.167 (0.758–1.797) 0.484	Lymph node metastasis					
Yes 0.907 (0.594–1.384) 0.65 1.167 (0.758–1.797) 0.484	No	1		1		
	Yes	0.907 (0.594–1.384)	0.65	1.167 (0.758–1.797)	0.484	

All eligible patients were randomly divided into two groups in a 1:1 ratio, which consisted of the training set and validation set. We used the training set for constructing nomograms and the validation set for validating nomograms.

Statistical Analysis

Univariate Cox regression analysis was first performed to analyze potential risk factors. Then we conducted multivariate Cox regression analysis to identify independent survival predictors. Meanwhile, hazard ratio (HR) and their 95% confidence interval (95% CIs) were presented in both univariate and multivariate analysis. Two-sided pvalue less than 0.05 was considered of significance. The above statistical analyses were carried out using the SPSS 23.0 software.

Nomograms were constructed and validated by using the R version 4.1.0 software¹ through comprehensive analysis of all

¹https://www.r-project.org/

TABLE 3 | Multivariate Cox regression analysis of survival in the training set.

independent predictors. We used the concordance index (Cindex) and calibration plots to assess the prognostic performance of the nomograms.

To achieve this purpose, bootstraps with 1,000 resamples were performed in both training and validation sets.

RESULTS

Clinicopathologic Characteristics

Ultimately, we identified 715 eligible young patients with BCBM from 2010 to 2016 in SEER, which consisted of 358 patients in the training set, and 357 patients in the validation set. The clinicopathologic characteristics of this special population were summarized in **Table 1**. White cases accounted for approximately 70%. Most patients were found in the 31-40 years age group (82.5%), with 20–30 years age group accounting for 17.5%. The distribution ratio of left and right tumor sites was similar. 47.5% of all cases were

Variable	OS		CSS	
	HR (95% CI)	Р	HR (95% CI)	Р
Race				
White	1		1	
Black	1.683 (1.135–2.497)	0.01	1.654 (1.106–2.476)	0.014
Others	0.966 (0.510-1.830)	0.916	1.296(0.731-2.296)	0.375
Tumor grade				
Low grade (I/II)	1		1	
High grade (III/IV)	1.335 (0.882-2.021)	0.172	1.138 (0.771–1.679)	0.515
Tumor subtype				
Luminal A	1		1	
Luminal B	0.553 (0.337–0.907)	0.019	0.517 (0.323–0.827)	0.006
HER2+	0.627 (0.343-1.146)	0.13	0.748 (0.423-1.324)	0.319
Triple-negative	3.774 (2.153-6.615)	< 0.001	5.349 (3.129-9.144)	< 0.001
Tumor size (cm)				
<3	1		1	
3–6	1.100 (0.711–1.704)	0.668	1.943 (1.245-3.034)	0.003
>6	1.721 (1.070–2.766)	0.025	2.203 (1.378-3.522)	0.001
Surgery				
Yes	1		1	
No	1.941 (1.302–2.893)	0.001	1.882 (1.295–2.735)	0.001
Radiotherapy				
Yes	1		-	
No	1.196 (0.815–1.754)	0.36	-	
Brain metastasis				
No	1		1	
Yes	3.015 (1.464–6.209)	0.003	4.028 (2.021-8.028)	< 0.001
Liver metastasis				
No	1		1	
Yes	1.540 (1.043–2.275)	0.03	1.528 (1.039–2.247)	0.031
Lung metastasis				
No	1		1	
Yes	1.748 (1.124–2.718)	0.013	2.214 (1.459–3.359)	< 0.001



pathologically graded as Grade I or II, and 54.3% were graded as Grade III or IV. The most common histological subtype was infiltrating duct carcinoma, NOS (84.3%). More than half of patients (53.0%) were Luminal A. Of this study population, 44.8% received surgery, 47.6% received radiotherapy, and 83.6% received chemotherapy. The proportions of these patients with brain metastasis, liver metastasis and lung metastasis were 5.2, 29.9, and 18.3%, respectively. It should be noted that the majority of patients (82.2%) had lymph node metastasis. The 3- and 5-year OS rates were 61.5 and 41.9%, respectively. The 3- and 5-year CSS rates were 62.6 and 43.3%, respectively.

Cox Regression Analyses

As shown in **Table 2**, nine significant variables of OS were identified by using univariate Cox regression analysis,

including race, tumor grade, tumor subtype, tumor size, surgery, radiotherapy, brain metastasis, liver metastasis, and lung metastasis. Race, tumor grade, tumor subtype, tumor size, surgery, brain metastasis, liver metastasis, and lung metastasis were shown to be significantly associated with CSS. Only significant survival predictors generated in univariate analysis were included in multivariate analysis. The detailed results of the multivariate analysis from the training set were summarized in **Table 3**. Seven independent predictors of both OS and CSS were identified, including race, tumor subtype, tumor size, surgery, brain metastasis, liver metastasis, and lung metastasis.

Nomogram Construction and Validation

Seven independent survival predictors revealed by multivariate analysis from the training set were incorporated in constructing



FIGURE 4 | Calibration curves for 3-year (A) and 5-year (B) overall survival; and 3-year (C) and 5-year (D) cancer-specific survival in the validation set. The X axis represents the nomogram predicted survival rate, whereas the Y axis represents the actual survival rate.

nomograms of OS (Figure 1) and CSS prediction (Figure 2). The C-index of the OS nomogram reached 0.728 and 0.73 in the training and validation sets, respectively. The C-index of the CSS nomogram reached 0.743 and 0.695 in the training and validation sets, respectively. The above results showed that these models had better discrimination ability. Then we further validated performance of nomograms by using calibration plots. As shown in Figures 3, 4, calibration plots showed high consistency between observed and predicted survival.

The nomogram summed the scores identified on the scale for each predictor. The total points projected on the bottom scales indicate the 3-year and 5-year survival rates of each patient. The specific scores assigned to each predictor were summarized in **Table 4**.

DISCUSSION

Although the diagnosis and treatment of BC has made great progress, the occurrence of bone metastasis brings great challenges to clinicians. Young patients diagnosed as BCBM are a rare group, and insufficient attention has been paid to them in the past. In the present study, we first defined the clinicopathological features and prognosis of this special population. More importantly, we developed an insightful and applicable tool to accurately predict the survival of them.

Young BCBM and overall BCBM have multiple similar clinicopathologic characteristics, such as distribution of race, laterality, tumor grade, histological type, tumor subtype (12, 14, 15). Interestingly, the prognosis of BC in young women

TABLE 4 Point assignment for	r each var	riable included i	n the nomograms.
--------------------------------	------------	-------------------	------------------

Variable	OS nomogram	CSS nomogram
Race		
White	0	0
Black	1.5	1.7
Others	2.9	3.4
Tumor subtype		
Luminal A	0	0
Luminal B	3.3	3.1
HER2+	6.7	6.2
Triple-negative	10	9.3
Tumor size (cm)		
<3	0	0
3–6	2.1	1.9
>6	4.2	3.9
Surgery		
Yes	0	0
No	8.42	5.5
Brain metastasis		
No	0	0
Yes	4.4	10
Liver metastasis		
No	0	0
Yes	3.2	2.2
Lung metastasis		
No	0	0
Yes	6	5.7

is usually poor, but for BC patients who developed bone metastasis, young women had a survival advantage. Our study showed the 5-year OS and CSS rates were 41.9 and 43.3%, respectively, which was higher than those of previous studies on BCBM (<34%) (12, 15). Notably, the proportion of young women with BCBM receiving various treatments (surgery, 44.8%; radiotherapy, 47.6%; chemotherapy, 83.6%) was higher than that of the overall BCBM patients (surgery, 36.4%; radiotherapy, 42.4%; chemotherapy, 62.3%) (12), indicating that they were more inclined to receive active therapies.

In the current study, we confirmed seven independent risk factors of both OS and CSS, including race, tumor subtype, tumor size, surgery, brain metastasis, liver metastasis, and lung metastasis, through both univariate analysis and multivariate Cox analysis. Based on these independent survival predictors, we constructed reliable graphical representation models to predict the survival of each young women with BCBM. To our knowledge, this was the first study to establish nomograms for predicting the prognosis of young patients with BCBM, which was of great significance in decision-making given the long survivorship period.

In recent years, the clinical application of nomograms has gradually increased, not only for predicting the prognosis of tumors, but also for predicting the outcome of nontumor diseases (16–18). Many previous studies indicated that cancer nomograms with C-index values ranging from 0.6 to 0.7, revealed good prognostic accuracy and clinical applicability (19, 20). The minimum C value of the nomogram in this study was 0.695, and the other three C values were all greater than 0.7, which indicated a better prognostic accuracy. In addition, the calibration curves showed the predicted probabilities produced by the nomograms in the training and validation sets were compared with the actual probabilities.

There are some shortcomings of this study. First, the study was a retrospective study based on SEER database, which has certain bias. Second, we cannot obtain all prognostic factors comprehensively from the SEER database. Third, due to the rarity of young BCBM, external validation was not conducted to further evaluate our nomograms. Even though nomogram-based clinical modeling is quite user-friendly, which can accurately calculate and predict the survival rate of each patient.

CONCLUSION

Our nomograms provide an effective approach for clinicians to assess the prognosis of young BCBM individually. However, further validation by multicenter clinical trials is needed to refine our models and promote its clinical application.

DATA AVAILABILITY STATEMENT

The raw data supporting the conclusions of this article will be made available by the authors, without undue reservation.

ETHICS STATEMENT

Ethical review and approval was not required for the study on human participants in accordance with the local legislation and institutional requirements. Written informed consent for participation was not required for this study in accordance with the national legislation and the institutional requirements.

AUTHOR CONTRIBUTIONS

ZW and ZY conceived and designed the study. ZW, HS, and QX collected the data. ZW, HS, QX, YW, YM, DD, and JZ performed the statistical analysis. ZW wrote the manuscript. HS, QX, YW, YM, and ZY revised the manuscript. All authors read and approved the final manuscript.

FUNDING

This work was supported by the China Postdoctoral Science Foundation (2021M692792), National Natural Science Foundation of China (82103499), and Zhejiang Provincial Natural Science Foundation (LQ22H160040).

REFERENCES

- Rossi L, Mazzara C, Pagani O. Diagnosis and treatment of breast cancer in young women. *Curr Treat Options Oncol.* (2019) 20:86. doi: 10.1007/s11864-019-0685-7
- Hu X, Myers KS, Oluyemi ET, Philip M, Azizi A, Ambinder EB. Presentation and characteristics of breast cancer in young women under age 40. *Breast Cancer Res Treat*. (2021) 186:209–17. doi: 10.1007/s10549-020-06000-x
- Eiriz IF, Vaz Batista M, Cruz Tomás T, Neves MT, Guerra-Pereira N, Braga S. Breast cancer in very young women-a multicenter 10-year experience. ESMO Open. (2021) 6:100029. doi: 10.1016/j.esmoop.2020.100029
- Shoemaker ML, White MC, Wu M, Weir HK, Romieu I. Differences in breast cancer incidence among young women aged 20-49 years by stage and tumor characteristics, age, race, and ethnicity, 2004-2013. *Breast Cancer Res Treat.* (2018) 169:595–606. doi: 10.1007/s10549-018-4699-9
- Slaoui M, Mouh FZ, Ghanname I, Razine R, El Mzibri M, Amrani M. Outcome of breast cancer in moroccan young women correlated to clinic-pathological features, risk factors and treatment: a comparative study of 716 cases in a single institution. *PLoS One.* (2016) 11:e0164841. doi: 10.1371/journal.pone.01 64841
- Liu W, Xiong XF, Mo YZ, Chen WG, Li M, Liang R, et al. Young age at diagnosis is associated with better prognosis in stage IV breast cancer. *Aging*. (2019) 11:11382–90. doi: 10.18632/aging.102536
- Venetis K, Piciotti R, Sajjadi E, Invernizzi M, Morganti S, Criscitiello C, et al. Breast cancer with bone metastasis: molecular insights and clinical management. *Cells*. (2021) 10:1377. doi: 10.3390/cells10061377
- Li W, Xiao Y, Xu X, Zhang Y. A novel nomogram and risk classification system predicting the cancer-specific mortality of patients with initially diagnosed metastatic cutaneous melanoma. *Ann Surg Oncol.* (2021) 28:3490–500. doi: 10.1245/s10434-020-09341-5
- Huang XT, Huang CS, Liu C, Chen W, Cai JP, Cheng H, et al. Development and validation of a new nomogram for predicting clinically relevant postoperative pancreatic fistula after pancreatoduodenectomy. *World J Surg.* (2021) 45:261– 9. doi: 10.1007/s00268-020-05773-y
- Liu H, Lv L, Qu Y, Zheng Z, Zhao J, Liu B, et al. Prediction of cancer-specific survival and overall survival in middle-aged and older patients with rectal adenocarcinoma using a nomogram model. *Transl Oncol.* (2021) 14:100938. doi: 10.1016/j.tranon.2020.100938
- Dai L, Wang W, Liu Q, Xia T, Wang Q, Chen Q, et al. Development and validation of prognostic nomogram for lung cancer patients below the age of 45 years. *Bosn J Basic Med Sci.* (2021) 21:352–63. doi: 10.17305/bjbms.2020. 5079
- Wang Z, Cheng Y, Chen S, Shao H, Chen X, Wang Z, et al. Novel prognostic nomograms for female patients with breast cancer and bone metastasis at presentation. *Ann Transl Med.* (2020) 8:197. doi: 10.21037/atm.2020. 01.37

- Wang Z, Wu B, Zhou Y, Huang X, Pan W, Liu M, et al. Predictors of the survival of primary and secondary older osteosarcoma patients. J Cancer. (2019) 10:4614–22. doi: 10.7150/jca.32627
- Liu D, Wu J, Lin C, Andriani L, Ding S, Shen K, et al. Breast subtypes and prognosis of breast cancer patients with initial bone metastasis: a populationbased study. *Front Oncol.* (2020) 10:580112. doi: 10.3389/fonc.2020.580112
- Li X, Zhang X, Liu J, Shen Y. Prognostic factors and survival according to tumour subtype in women presenting with breast cancer bone metastases at initial diagnosis: a SEER-based study. *BMC Cancer.* (2020) 20:1102. doi: 10.1186/s12885-020-07593-8
- Su Y, Yuki M, Hirayama K, Otsuki M. Development and internal validation of a nomogram to predict post-stroke fatigue after discharge. *J Stroke Cerebrovasc.* (2021) 30:105484. doi: 10.1016/j.jstrokecerebrovasdis. 2020.105484
- Dong YM, Sun J, Li YX, Chen Q, Liu QQ, Sun Z, et al. Development and validation of a nomogram for assessing survival in patients with COVID-19 pneumonia. *Clin Infect Dis.* (2021) 72:652–60. doi: 10.1093/cid/ciaa963
- Deng F, Peng M, Li J, Chen Y, Zhang B, Zhao S. Nomogram to predict the risk of septic acute kidney injury in the first 24 h of admission: an analysis of intensive care unit data. *Renal Fail.* (2020) 42:428–36. doi: 10.1080/0886022x. 2020.1761832
- Zuo Z, Zhang G, Song P, Yang J, Li S, Zhong Z, et al. Survival nomogram for stage IB non-small-cell lung cancer patients, based on the SEER database and an external validation cohort. *Ann Surg Oncol.* (2021) 28:3941–50. doi: 10.1245/s10434-020-09362-0
- Lin S, Mo H, Li Y, Guan X, Chen Y, Wang Z, et al. Development and validation of a nomogram for predicting survival of advanced breast cancer patients in China. *Breast.* (2020) 53:172–80. doi: 10.1016/j.breast.2020.08.004

Conflict of Interest: The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Publisher's Note: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.

Copyright © 2022 Wang, Shao, Xu, Wang, Ma, Diaty, Zhang and Ye. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.